MRNA · News · 20260803N

Market Demand Trends

Moderna, Inc. · 2026-08-03 · Importance 20 · Surprise 24

Moderna continues to face weak demand for its COVID-19 vaccines as pandemic-era sales decline. COVID vaccine sales remain a significant influence on the company’s top line, creating pressure as Moderna transitions toward a broader vaccine and therapeutics portfolio. The company is seeking to offset the decline with its seasonal flu vaccine and a future COVID-flu combination product.

Key facts

• MarketBeat reported Amundi reduced its Moderna stake by 20.9% in the first quarter, selling 238,790 shares and retaining 904,823 shares valued at approximately $46 million. source
• MarketBeat reported Militia Capital Management LLC acquired 23,001 shares of Moderna worth approximately $1.168 million in the first quarter. source